Denileukin Diftitox BLA Resubmitted for CTCL After Addressing FDA Concerns

The biologics license application for denileukin diftitox has been resubmitted to the FDA for the treatment of cutaneous T-cell lymphoma after at least 1 prior systemic therapy.

Related Keywords

Japan ,Davida Litman ,Citius Pharmaceuticals Inc ,Citius Pharmaceuticals ,Prescription Drug User Fee Act ,News ,Articles ,February 2024 ,Fda ,Lymphomas ,Denileukin Diftitox ,Bla ,Biologics License Application ,Ctcl ,Pdufa ,Complete Response Letter ,Lymphir ,